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Background: We lack reliable methods for predicting myocardial infarction in patients with 
established coronary artery disease. Coronary 18F-sodium fluoride (18F-NaF) positron emission 
tomography (PET) provides an assessment of atherosclerosis activity.  
Objectives: We assessed whether 18F-NaF PET predicts myocardial infarction and provides 
additional prognostic information to current methods of risk stratification. 
Methods: Patients with known coronary artery disease underwent 18F-NaF PET computed 
tomography and were followed-up for fatal or non-fatal myocardial infarction over 42 [31-49] 
months. Total coronary 18F-NaF uptake was determined using coronary microcalcification 
activity (CMA). 
Results: In a post-hoc analysis of data collected for prospective observational studies we studied 
293 study participants (65±9 years; 84% male), of whom 203 (69%) showed increased coronary 
18F-NaF activity (CMA>0). Fatal or non-fatal myocardial infarction occurred only in patients 
with increased coronary 18F-NaF activity (20/203 CMA>0 versus 0/90 CMA=0; p<0.001). On 
receiver operator-curve analysis, fatal or non-fatal myocardial infarction prediction was highest 
for 18F-NaF CMA, outperforming coronary calcium scoring, modified Duke coronary artery 
disease index, REACH and SMART risk scores (areas under curve: 0.76 versus 0.54, 0.62, 0.52 
and 0.54; p<0.001 for all). Patients with CMA>1.56 had >7-fold increase in fatal or non-fatal 
myocardial infarction (hazard ratio 7.1, 95% confidence interval 2.2 to 25.1; p=0.003) 
independent of age, gender, risk factors, segment involvement and coronary calcium scores, 
presence of coronary stents, coronary stenosis, REACH and SMART scores, the Duke coronary 
artery disease index and recent myocardial infarction. 
Conclusion: In patients with established coronary artery disease, 18F-NaF PET provides 
powerful independent prediction of fatal or non-fatal myocardial infarction. 
 
Keywords: 18F-NaF PET, coronary computed tomography, coronary artery disease, myocardial 
infarction, coronary event risk prediction 
 
Condensed abstract  
We assessed whether 18F-NaF PET predicts myocardial infarction and provides additional 
prognostic information to current methods of risk stratification. Patients with known coronary 
artery disease underwent contrast-enhanced 18F-NaF PET computed tomography and were 
followed-up for myocardial infarction over 42 [31-49] months. Among 293 study participants 
myocardial infarction occurred only in patients with increased coronary 18F-NaF activity. 
Patients with increased 18F-NaF uptake had >7-fold increase in myocardial infarction 
independent of age, gender, cardiovascular risk factors, segment involvement scores, presence of 
coronary stents, number of vessels with significant stenosis, coronary calcium scoring, REACH 
and SMART scores, the Duke index, initial patients presentation (acute coronary syndrome or 
stable) and the study in which individuals were initially recruited. 
 
Abbreviations and acronyms 
CMA  Coronary Microcalcification Activity 
CT  Computed Tomography 
MACE Myocardial Adverse Cardiovascular Events 
PET  Positron Emission Tomography 
SD  Standard Deviation 
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SUV  Standard Uptake Value 
TBR  Maximum Target to Background Ratio 




Despite improvements in therapies for atherosclerotic disease, myocardial infarction remains a 
leading cause of death worldwide. Robust tools to identify patients at risk of myocardial 
infarction would be extremely valuable as they could facilitate the targeted application of novel 
or intensive therapies to patients at the highest risk of events or down escalation of therapy in 
patients at low risk. However, to date, risk prediction in patients with established coronary artery 
disease has proven challenging. Current approaches are based around clinical risk scores, 
anatomic assessments of coronary artery calcification and the severity of obstructive coronary 
stenoses (1). These approaches have shown limited predictive value in patients with established 
coronary artery disease and there is growing interest in novel risk stratification methods, 
including assessments of atherosclerotic disease activity (2), that might be used to target 
expensive yet effective new treatments to patients at highest risk.  
Advanced positron emission tomography (PET) imaging can provide assessment of 
disease activity in the coronary arteries to complement the anatomic plaque imaging provided by 
computed tomography (CT). The PET tracer 18F-sodium fluoride (18F-NaF) is a marker of 
developing microcalcification and calcification activity across multiple different cardiovascular 
disease states (3). In coronary and carotid atherosclerosis, 18F-NaF localizes to culprit plaques 
following myocardial infarction and stroke as well as to plaques with multiple adverse 
characteristic in patients with stable disease (4-6). Moreover, coronary 18F-NaF uptake has 
demonstrated its ability to predict disease progression and change in coronary calcium score, 
similar to results in other cardiovascular conditions (7-9). While coronary 18F-NaF uptake 
appears to provide a marker of atherosclerosis disease activity, the prognostic significance of 
increased coronary 18F-NaF activity is unknown. 
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In this study, we investigated whether coronary 18F-NaF PET uptake predicts future myocardial 
infarction and MACE in patients with established coronary artery disease, and whether it can 
provide additional prognostic information over and above current methods of risk stratification 
including clinical risk scores, coronary calcium scoring and the severity of obstructive coronary 
artery disease.   
Methods 
Study Design and Participants 
Patients with established coronary artery disease undergoing hybrid coronary  18F-NaF PET and 
contrast CT angiography at the Edinburgh Heart Centre and Cedars-Sinai Medical Center within 
prospective observational research studies were included in the current post-hoc analysis 
(NCT01749254, NCT02110303, NCT02607748) (4,10). The study cohort comprised patients 
with recent myocardial infarction or established stable angina pectoris undergoing elective 
invasive coronary angiography (inclusion and exclusion criteria have been presented in the 
Online Appendix). All patients underwent a comprehensive baseline clinical assessment 
including evaluation of their cardiovascular risk factor profile. In particular, REACH [Reduction 
of Atherothrombosis for Continued Health] and SMART [Secondary Manifestations of Arterial 
Disease] risk scores were calculated (Online Appendix). Both these scores were created 
specifically to predict risk in patients with established coronary artery disease (1,11). Patients 
also underwent hybrid 18F-NaF PET imaging alongside coronary CT calcium scoring and 
coronary CT angiography. Studies were conducted with the approval of the local research ethics 
committee, in accordance with the Declaration of Helsinki, and with the written informed 
consent of each participant. 
18F-Sodium Fluoride and CT imaging 
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Acquisition and reconstruction 
All patients underwent 18F-NaF PET on hybrid PET/CT scanners (128-slice Biograph mCT, 
Siemens Medical Systems, Knoxville, USA or Discovery 710 GE Healthcare, Milwaukee, WI, 
USA) using harmonized imaging protocols 60 min following intravenous 18F-NaF 
administration. During a single imaging session, we acquired a non-contrast CT attenuation 
correction scan followed by a 30-min PET emission scan in list mode. The electrocardiogram 
(ECG)-gated list mode dataset was reconstructed using a standard ordered expectation 
maximization algorithm with time-of-flight, and point-spread-function correction. Using 4 
cardiac gates, the data were reconstructed on a 256x256 matrix (with 75 or 47 slices using 2 
iterations, 21 subsets and 5-mm Gaussian smoothing or 4 iterations, 24 subsets and 5-mm 
gaussian smoothing for Biograph and Discovery respectively). Immediately after the PET scan, a 
low dose non-contrast ECG-gated CT for calculation of the coronary calcium score was 
performed. Subsequently, a contrast-enhanced, ECG-gated coronary CT angiogram was obtained 
in mid-diastole on the same PET/CT system without repositioning the patient. To compensate for 
coronary motion associated with heart contraction, we performed cardiac motion correction of 
the PET/CT images (Online Appendix) (12,13).  
Image analysis 
Computed Tomography 
The coronary artery calcium score was measured in Agatston units (AU) using clinical software 
(NetraMD, ScImage, Los Altos, CA, USA). The presence of coronary atherosclerosis, and the 
extent and severity of obstructive coronary artery disease, was evaluated on contrast-enhanced 
CT angiography by defining the segment involvement score; the number of vessels with >50% 
luminal stenosis; and the modified Duke coronary artery disease index (combining the extent, 
7 
 
severity, and location of coronary stenoses) (14). Multivessel coronary artery disease was 
defined as at least 2 major epicardial vessels with any combination of either >50% stenosis, or 
previous revascularization.  
18F-Sodium Fluoride 
We used a dedicated software package for coronary PET image analysis (FusionQuant, Cedars-
Sinai Medical Center, Los Angeles). PET and CT angiography reconstructions were reoriented, 
fused and systematically co-registered in 3 orthogonal planes (15). We used two methods to 
evaluate coronary 18F-NaF activity: the maximum target to background (TBR) approach 
(standard quantification) which relies on visual detection of lesions with increased tracer uptake; 
and the newly developed whole-coronary total microcalcification activity method (novel 
quantification) (4,16).  
Target to Background Ratio quantification  
On co-registered PET and CT angiography images, for a signal to be co-localized to a coronary 
artery, an atherosclerotic plaque had to be present on the CT angiogram and the increased pattern 
of radiotracer had to arise from the coronary artery and follow its course in three dimensions on 
3-orthogonal views (3). In all plaques meeting these criteria, maximum standardized uptake 
values (SUVmax) were measured within manually drawn regions of interest. TBR values were 
calculated by dividing the coronary SUVmax by the blood pool activity measured in the right 
atrium (mean SUV in cylindrical volumes of interest at the level of the right coronary artery 
ostium: radius 10 mm and thickness 5 mm).  
Blood clearance correction  
To offset for variation in the delay between tracer injection and scanning, which has a major 
impact on blood pool activity, we used a recently validated correction factor to harmonize the 
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background activity to a reference 60-minute injection-to-acquisition interval (Online Appendix) 
(17).  
Coronary microcalcification activity (CMA) quantification 
We used a recently described measure of coronary 18F-NaF uptake, that quantifies PET activity 
across the entire coronary vasculature based upon analysis widely employed in oncology and 
cardiac sarcoidosis (16,18,19). First, we automatically extracted whole-vessel tubular and 
tortuous 3D volumes of interest from CT angiography datasets (Central Illustration, Online 
Appendix). These encompass all the main epicardial coronary vessels and their immediate 
surroundings (4-mm radius) facilitating per-vessel and per-patient uptake quantification. Within 
such volumes of interest, we measured the coronary microcalcification activity (CMA)— 
representing the overall disease activity in the vessel and based upon both the volume and 
intensity of 18F-NaF PET activity within it (similar in principle to the Agatston score used for CT 
calcium scoring). CMA was defined as the integrated activity in SUV units exceeding the 
corrected background blood-pool mean SUV + 2 standard deviations (right atrium activity). The 
per-patient CMA was defined as the sum of the per-vessel CMA values. 
Clinical Follow-up 
The primary endpoint of the study was fatal or non-fatal myocardial infarction. The secondary 
endpoint was major adverse cardiovascular events (MACE), defined as myocardial infarction, 
stroke, delayed revascularization (more than 6 months after PET/CT) and cardiovascular death. 
Outcome information including invasive coronary angiography and coronary revascularization 
(percutaneous coronary intervention or coronary artery bypass graft surgery) were obtained from 
the local and national healthcare record systems that integrates primary and secondary health 
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care records. Categorization of these outcomes was performed blinded to the coronary PET or 
other study data. Outcome data were collected in July 2019. 
Statistical analysis 
We assessed the distribution of data with the Shapiro-Wilk test. Continuous parametric variables 
were expressed as mean (SD) and compared using Student's t tests. Non-parametric data were 
presented as median [Q1-Q3] and compared using Mann-Whitney U test. Fisher's exact test or 
chi-squared test was used for analysis of categorical variables. We used the receiver-operating 
characteristic (ROC) analysis and pairwise comparisons according to DeLong et al to compare 
areas under the curves. Kaplan-Meier curves were used to elucidate the survival distributions 
with regard to myocardial infarction and MACE. Differences in the outcome of patients with and 
without 18F-NaF coronary activity exceeding the threshold derived from the ROC using 
Youden’s index were assessed using the log-rank test. A Cox proportional hazard regression with 
adjustment for potential confounders was performed to determine the predictors of worse 
outcome. Statistical analysis was performed with SPSS version 24 (IBM SPSS Statistics for 




The study population comprised 293 patients (84% males, mean age: 65±9 years). All 
participants had established coronary artery disease, the majority (n=232) had stable disease and 
the remaining 61 individuals were recruited and imaged (14 [10-19)] days) following recent (7 
[3-11] days) myocardial infarction (Online Appendix). Patients had advanced coronary 
atherosclerosis with a high burden of cardiovascular risk factors (hypertension 60%, 
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hyperlipidemia 88%, tobacco use 67%, REACH clinical risk scores of 13 [11-15], SMART 
clinical risk scores of 18 [13-26]), widespread utilization of secondary preventative therapies 
(statin 90%, anti-platelet therapy 92%, ACE inhibitor or angiotensin receptor blockers  67%) and 
high rates of prior revascularization (n=237, 81%). None of the patients were taking PCSK9 
inhibitor or interleukin 1-beta inhibitor therapy. On invasive angiography, 87 (30%) individuals 
had single vessel obstructive disease, 191 (65%) had multi-vessel obstructive coronary artery 
disease, and 18 (6%) had left main stem involvement.  
Computed Tomography 
Patients had advanced coronary artery disease on CT. The median CT calcium score was 334 
[76-804], 59 (20%) subjects had a calcium score > 1000, 133 (45%) patients had a score > 400, 
and only 84 (29%) presented with a score <100. On coronary CT angiography, the overall 
median segment involvement score was 5 [3-7] with three-quarters of patients (n=218, 74%) 
having at least 4 segments involved (Online Appendix). The median modified Duke index was 4 
[3-5]. 
Positron Emission Tomography 
On visual analysis of coronary PET, we identified increased tracer activity in 208 (70.9%) 
patients. Across the entire cohort, we found a median TBR of 1.22 [1.10-1.42]. Compared to 
those without uptake, patients with increased coronary 18F-NaF uptake had higher SMART risk 
scores (17 [13-23] vs 19 [13-27], p=0.029), and higher coronary calcium scores (184 [50-528] vs 
371 [102-974] AU, p=0.0031), but there was no difference in the presence or severity of 




Assessing whole vessel microcalcification activity, 203 (69.3%) patients presented with CMA>0. 
The median CMA value was 0.66 [0-2.84]. Again, we observed that patients with a CMA>0 had 
higher SMART risk scores (17 [13-23] vs 19 [13-27], p=0.028) and increased coronary calcium 
scores (378 [103-993] vs 179 [48-529], p=0.003) than subjects with CMA=0, but there was no 
difference in the presence or severity of obstructive coronary stenoses (all p>0.10; Online 
Appendix).  
Clinical Outcomes 
Over the 42 [31-49] months of follow-up, 20 subjects experienced a fatal (n=3) or non-fatal 
(n=17) myocardial infarction. Seven of these occurred in patients imaged following an acute 
coronary syndrome who had a median time from PET/CT to recurrent myocardial infarction of 
12 (6-15) months. During follow-up a total of 40 patients suffered a MACE event (20 myocardial 
infarctions, 12 strokes, 3 cardiovascular deaths and 5 cases of delayed revascularization) 
Primary endpoint: fatal or non-fatal myocardial infarction 
Patients who experienced myocardial infarction during follow-up had higher TBR values than 
those who did not (1.40 [1.28-1.77] versus 1.21 [1.09-1.40], p=0.006) and CMA (3.05 [1.62-
5.25] versus 0.46 [0-2.47], p=0.002; Figure 1). Indeed, all the patients who had an infarct had 
increased coronary 18F-NaF PET uptake at baseline (CMA > 0). Interestingly, patients who 
experienced a fatal or non-fatal myocardial infarction did not have increased clinical risk scores 
(REACH: 13 [11-15] versus 13 [11-15], p=0.79; SMART 20 [13-28] versus 18 [13-26], p=0.52) 
nor coronary calcium scores (397 [39-1456] versus 331 [76-775] AU, p=0.60) compared to 
patients who did not have an infarct. Moreover, they did not have an increased prevalence of 
obstructive coronary artery disease (segment involvement score 6 [4-8] versus 5 [3-7], p=0.25), 
multivessel coronary disease (70% versus 65%, p=0.64) nor previous coronary stents (75% 
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versus 74%, p=1.00). In patients who had a fatal or non-fatal myocardial infarction, 30% had a 
coronary calcium score <100 AU, 20% were within the 100-399 AU range, 20% were within the 
400-999 AU range and 30% had a coronary calcium score >1000 AU (Figures 2 & 3). Only 12% 
(7/59) of patients with coronary calcium score >1000 AU experienced myocardial infarction 
(Online Appendix).  
On ROC analysis, both CMA and TBR showed a greater area under the curve for the 
prediction of myocardial infarction than coronary calcium scores, or the REACH and SMART 
clinical risk scores (Online Appendix). In order to generate distinct clinical risk groups, we 
dichotomized the population according to their coronary 18F-NaF uptake and derived the optimal 
TBR and CMA cutoffs for event prediction using the Youden’s index. A threshold of 1.56 for 
CMA achieved a specificity and sensitivity of 66% and 80% for the primary endpoint. A 
threshold of 1.28 for TBR achieved a specificity of 63% and sensitivity of 80% (Table 1). On 
univariable Cox proportional regression, both CMA >1.56 (hazard ratio (HR) 7.30, 95% 
confidence interval (CI) 2.44-21.84; p<0.001) and TBR >1.28 (HR 6.16, 95% CI 1.06-18.42; 
p=0.001) emerged as predictors of fatal or non-fatal myocardial infarction. Importantly, these 
associations persisted on multivariable analysis after adjustments for gender, comorbidities 
(presence of hypertension, hyperlipidemia, diabetes, smoking), the segment involvement score, 
number of coronary stents, multivessel coronary artery disease, coronary calcium score, SMART 
and REACH risk scores, initial patients presentation (acute coronary syndrome or stable 
coronary artery disease) and the study in which individuals were initially recruited (Figure 4). 
Indeed patients with CMA>1.56 had an adjusted hazard ratio of 7.1 (95% CI 2.2 to 25.1; 
p=0.003) for the primary end point, whilst patients with a TBR >1.28 had an adjusted hazard 
ratio of 4.6 (95% CI 1.4 to 14.4, p=0.013; Table 2). Similar results were observed when both 
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CMA and TBR were considered as continuous variables, with both again emerging as the only 
independent predictors of fatal or non-fatal myocardial infarction on Cox modelling (Online 
Appendix). In contrast, the number of stenosed vessels, the modified Duke index, age, and the 
SMART and REACH risk scores did not emerge as predictors of fatal non-fatal myocardial 
infarction on univariable Cox modelling (all p>0.1, Online Appendix). Coronary calcium score 
was a predictor of events on univariable but not multivariable analysis (Table 2). Despite low 
statistical power when patients with acute myocardial infarction and stable subjects were 
considered separately, the AUCs on receiver-operator-characteristic curve analyses remained 
numerically similar (Online Appendix).  
Secondary Endpoint: Major Adverse Cardiovascular Events 
Patients with MACE had higher CMA (1.9 [1.65-4.76] versus 0.51 [0-2.42], p=0.0098) and an 
apparent trend for higher TBR values (1.34 [1.13-1.54] versus 1.22 [1.10-1.40], p=0.073) than 
patients without MACE. There were no differences in the extent of obstructive coronary artery 
disease on CT angiography (the segment involvement score, the modified Duke index, presence 
of multivessel disease or coronary stents) nor cardiovascular risk scores and co-morbidities in 
patients with and without MACE (Online Appendix). Similarly, there was no difference in 
coronary calcium scores 195 [50-1126] versus 344 [81-801] AU, p=0.50). Only 17% (10/59) of 
patients with a coronary calcium score >1000 AU experienced MACE.  
On univariable Cox proportional regression, both CMA>1.56 and TBR>1.28 were 
predictors of MACE (HR 2.3, 95% CI 1.2-4.3, p=0.01 and HR 2.1, 95% CI 1.1-3.9, p=0.02). On 
multivariable analysis after adjustments for age, gender, comorbidities (presence of 
hypertension, hyperlipidemia, diabetes, smoking), the segment involvement score, number of 
coronary stents multivessel coronary artery disease, coronary calcium score and the REACH and 
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SMART risk scores, CMA remained the only independent predictor of MACE (HR 2.1, 95% CI 
1.1-4.1, p=0.030; Figure 4). When CMA and TBR were considered as continuous variables, 
these two measurements emerged as the only predictors of MACE on Cox modelling (Online 
Appendix). 
In contrast, coronary calcium score exceeding 1199 AU (HR 1.9, 95% CI 0.9-4.0, 
p=0.07) , the modified Duke index (HR 1.2, 95% CI 0.9-1.6, p=0.14), the REACH (HR 1.7, 95% 
CI 0.5-5.5, p=0.38) and SMART (HR 1.5, 95% CI 0.8-2.8, p=0.23) risk scores were not 
predictors of MACE on univariable analysis. 
Discussion 
In this two-center multimodality imaging study, we have demonstrated for the first time that 
coronary 18F-NaF PET is a powerful prognostic tool for predicting myocardial infarction in 
patients with advanced established coronary artery disease. In a comprehensive analysis, we 
show that both 18F-NaF TBR values and whole vessel CMA emerge as powerful independent 
predictors of myocardial infarction outperforming all other established predictors including the 
presence of co-morbidities, the REACH and SMART risk scores, coronary calcium scoring and 
the presence, severity and extent of coronary artery disease. Our data therefore highlight the 
added prognostic value that assessments of disease activity can provide and confirm the potential 
of 18F-NaF PET to improve the risk stratification of patients with established CAD, a group in 
whom prediction of events has previously proved challenging. 
18F-NaF PET provides an assessment of calcification activity across multiple different 
cardiovascular disease states including aortic stenosis, mitral annular calcification, abdominal 
aortic aneurysm, erectile dysfunction and bioprosthetic valve degeneration (7,20). In each 
condition, it is associated with vascular injury, disease activity and future disease progression. 
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This is also the case in coronary atherosclerosis. Increased 18F-NaF uptake is associated with 
culprit coronary plaques in patients with myocardial infarction and adverse plaque features in 
patients with apparently stable disease (4). Moreover, similar to other cardiovascular conditions, 
baseline coronary 18F-NaF activity predicts the future progression of coronary calcium scores, 
confirming its status as a marker of disease activity (5,6). While there is major interest in using 
markers of atherosclerotic disease activity to improve patient assessment and risk stratification, 
this is the first study to demonstrate that increased 18F-NaF activity provides powerful prediction 
of future myocardial infarction. Indeed, this technique outperformed all the other commonly used 
predictors of events in patients with established coronary artery disease including two established 
clinical risk scores designed for this patient population, co-morbidities, coronary calcium 
scoring, and the presence and severity of obstructive coronary artery disease. 18F-NaF might 
therefore provide an important clinical tool in a patient population in whom risk stratification is 
currently suboptimal. A CMA >1.56 was associated with a >7-fold risk of myocardial infarction. 
This was despite almost universal prescription of aspirin, statins and other secondary 
preventative therapies. These patients might therefore be suitable for advanced medical therapies 
including PCSK9 or interleukin 1-beta inhibition, with 18F-fluoride PET providing the risk 
stratification tool that many have advocated for as a means of targeting these expensive drugs to 
those patients at greatest risk. In the wake of the ISCHEMIA trial this approach might also help 
select patients who would benefit from revascularization (21). Of equal importance, patients 
without coronary 18F-NaF uptake and a CMA=0 had an excellent prognosis with no myocardial 
infarctions observed in this group despite their advanced coronary artery disease. In these 
patients with dormant coronary artery disease (a third of the population studied), further 
intensification of medical therapy might not be warranted, nor might they benefit on prognostic 
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grounds from complex revascularization such as multivessel percutaneous intervention or 
coronary artery bypass grafting. Further research is required to investigate these important 
clinical questions.  
Our data demonstrating the modest predictive value of cardiovascular risk scores, 
coronary calcium scoring and obstructive coronary artery disease in patients with advanced 
established coronary artery disease is consistent with the recent literature. The diagnostic 
performance of the REACH and SMART risk scores was poor in several recent studies (C‐
statistic of 0.53 and 0.54 respectively (1,22). While coronary calcium scoring provides powerful 
prognostic information in asymptomatic individuals and those presenting with chest pain, its 
prognostic capability has been disappointing in other studies of patients with established 
advanced coronary artery disease (23,24). In line with recent literature, the presence and extent 
of obstructive coronary artery disease was also not a marker of adverse events in our study 
(25,26). 
Our study has notable strengths. We have focused our analysis on patients with advanced 
established coronary artery disease for whom we lack robust methods for risk stratification and 
showed that 18F-NaF PET has the potential to fulfill this unmet clinical need. We utilized state-
of-the-art 18F-NaF PET imaging, employing the latest advances in image acquisition and motion 
correction (14). We also employed a novel quantification technique, CMA, that measures 18F-
NaF uptake along the course of the entire coronary vasculature and therefore provides a more 
complete summative assessment of disease activity than the TBR values derived from visually 
defined hot spot assessments (16). While both standard TBR values and CMA emerged as 
independent predictors of myocardial infarction, CMA demonstrated a superior hazard ratio for 
this endpoint, and was also the only independent predictor of MACE. CMA would therefore 
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appear to hold advantages as a method for quantifying overall coronary 18F-NaF uptake and 
disease activity.  
Limitations 
Our study has some limitations. It is a post-hoc analysis of data collected for prospective 
observational studies. While all the subjects had advanced established coronary artery disease, 
we have included patients with both stable and unstable coronary artery disease thereby 
increasing the heterogeneity of the analyzed cohort. Similar results were, however, observed 
when patients with unstable coronary artery disease were excluded from the analysis (online 
appendix). Our data therefore require confirmation in large prospective studies. Indeed, we are 
currently completing recruitment for the Prediction of Recurrent Events With 18F-Fluoride 
(PREFFIR) study which will prospectively investigate the ability of 18F-NaF coronary PET to 
predict recurrent events in patients with multi-vessel disease and recent myocardial infarction. 
While performing a CT angiogram alongside the 18F-NaF PET scan incurs a modest additional 
dose of radiation, this is currently essential for accurate image co-registration, interpretation and 
analysis (15). Although we have shown that delayed 18F-NaF imaging may improve image 
quality, in this study participants underwent PET imaging 1 h after tracer injection (27). The 
potential prognostic benefits of delaying image acquisition therefore remain to be evaluated.   
Conclusions 
18F-NaF PET is a determinant of disease activity in the coronary arteries and a powerful 
prognostic technique to predict myocardial infarction in patients with advanced established 
coronary artery disease.  Further studies are required to confirm our findings and to investigate 
how best to use this technique to improve patient risk stratification and to guide the use of 




COMPETENCY IN MEDICAL KNOWLEDGE: 18F-NaF coronary PET provides an assessment 
of disease activity in coronary atherosclerosis and powerful independent prediction of 
myocardial infarction in patients with established coronary artery disease.  
TRANSLATIONAL OUTLOOK: 18F-NaF PET holds promise in risk stratifying patients with 
established coronary artery disease and as a tool to up titrate therapy (e.g. PCSK9 and interleukin 
1-beta inhibition) in those at high risk, whilst down grading therapy and intervention in patients 
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Figure 1. Coronary disease activity and plaque burden in patients with and without future 
myocardial infarction. Coronary microcalcification activity (CMA, top row), maximum target 
to background ratios (TBR, middle row) and the coronary calcium scores (CCS, bottom row) in 
patients with and without myocardial infarction during follow-up. For the Kaplan-Meier curves 
patients were dichotomized according to thresholds derived from receiver operator curves using 
the Youden’s index: CMA=1.56, TBR=1.28 and coronary calcium score = 1199 Agatston-units. 
Figure 2. Case examples of 18F-sodium fluoride positron emission tomography in patients 
with established coronary artery disease and myocardial infarction during follow-up. 
Hybrid CT angiography and 18F-NaF positron emission tomography of coronary arteries in: (A) a 
56-year-old male who demonstrated increased 18F-NaF uptake in the RCA at baseline and 
presented with an inferior ST-segment elevation myocardial infarction and occlusion of the RCA 
during follow-up; (B) a 52-year-old male who demonstrated increased 18F-NaF uptake in the 
LCx at baseline and presented with a lateral non-ST-segment elevation myocardial infarction 
during follow-up; (C) a 60-year-old female who showed increased 18F-NaF uptake in the 
proximal RCA and presented with an inferior non-ST-segment elevation myocardial infarction 
during follow-up. LAD–left anterior descending, LCx–left circumflex, RCA–right coronary 
artery. 
Figure 3. 18F-sodium fluoride positron emission tomography in the prediction of 
myocardial infarction in patients with established coronary artery disease. In patients with 
established atherosclerosis the coronary microcalcification activity (as a marker of 18F-NaF 
activity across the coronary vasculature) had a significantly larger area under the receiver 
operator curve than the coronary calcium score (non-contrast CT), the modified Duke index 
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(contrast CT angiography) or the REACH score (patient clinical data).AU-Agatston units, 
CMA–coronary microcalcification activity, REACH-Reduction of Atherothrombosis for 
Continued Health 
Figure 4. Predictors of myocardial infarction on Cox proportional hazards modelling. 
Forest plots of hazard ratios derived from multivariable modelling with 95% confidence intervals 
for the coronary microcalcification activity (CMA) (A) and the target to background ratio values 
(B) along with covariates: coronary calcium scores, SIS, REACH score, SMART score, total 
number of implanted coronary stents, presence of multivessel coronary artery disease, age, 
gender, hyperlipidemia, hypertension, diabetes, smoking. CMA–coronary microcalcification 
activity, REACH-Reduction of Atherothrombosis for Continued Health, SMART - Secondary 
Manifestations of Arterial Disease, SIS–segment involvement score, TAG-triacylglycerides, 
TBR–target to background ratio 
Central Illustration.  18F-sodium fluoride positron emission tomography as a marker of 
disease activity in the coronary arteries is a predictor of fatal or non-fatal myocardial 
infarction (MI) in patients with established coronary artery disease. 18F-fluoride PET can be 
used to measure disease activity across the coronary vasculature and to stratify patients into those 
with no, low and high disease activity. Patients with high disease activity (coronary 
microcalcification activity (CMA) >1.56) demonstrate a >7-fold risk of myocardial infarction. 
These patients might therefore be suitable for advanced medical therapies including PCSK9 or 
interleukin 1-beta inhibition, with 18F-fluoride PET used for targeting these expensive drugs to 
patients at greatest risk. Patients without coronary 18F-NaF uptake (CMA=0) have an excellent 
prognosis with no myocardial infarctions observed during follow-up despite advanced coronary 
artery disease. In these patients with dormant coronary artery disease (a third of the population 
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studied), further intensification of medical therapy might not be warranted, nor might they 
benefit on prognostic grounds from complex revascularization such as multivessel percutaneous 




Table 1. Baseline Characteristics of Study Participants. Comparison of patients with coronary microcalcification activity (CMA) 
≥1.56 vs <1.56, with Target to Background ratio (TBR) ≥1.28 vs <1.28 and coronary calcium score ≥1199 vs <1199.  
 CMA TBR CCS 













Age in years, mean (SD) 67 (8) 64 (9) 0.0047 67 (8) 63 (9) 0.0001 68 (8) 64 (9) 0.006 
Men, n (%) 97 (89%) 148 (80%) 0.071 103 (91%) 142 (79%) 0.006 44 (98%) 201 (81%) 0.004 
Body-mass index (kg/m2), mean 
(SD) 
28 (5) 30 (5) 0.024 29 (6) 29 (5) 1.00 30 (5) 29 (5) 0.22 
Systolic blood pressure (mm Hg), 
mean (SD) 
142 (21) 141 (20) 0.68 142 (20) 141 (20) 0.68 143 (15) 141 (21) 0.54 
Diastolic blood pressure (mm Hg), 
mean (SD) 
79 (12) 80 (11) 0.46 78 (11) 80 (12) 0.15 78 (11) 80 (11) 0.26 
Cardiovascular history, n (%)  
H of ACS 53 (48.6%) 108 (58.7%) 0.11 58 (51.3%) 103 (57.2%) 0.34 25 (55.6%) 136 (54.8%) 1.00 
H of PCI 64 (58.7%) 119 (64.7%) 0.32 69 (61.1%) 114 (93.3%) 0.71 23 (51.1%) 160 (64.5%) 0.10 
H of CABG 20 (18.3%) 28 (15.2%) 0.52 21 (18.6%) 27 (15.0%) 0.44 23 (51.1%) 25 (10.1%) 0.0001 
H of angina 60 (55.0%) 76 (41.3%) 0.029 57 (50.4%) 79 (43.9%) 0.28 30 (66.7%) 106 (42.7%) 0.003 
CVA/TIA 3 (2.8%) 6 (3.3%) 1.000 3 (2.7%) 6 (3.3%) 1.00 1 (2.2%) 8 (3.2%) 1.00 
Comorbidities/risk factors, n 
(%) 
 
HTN 71 (65.1%) 103 (55.9%) 0.14 76 (67.3%) 98 (54.4%) 0.038 30 (66.7%) 144 (58.1%) 0.32 
HPL 97 (89.0%) 160 (86.9%) 0.71 101 (89.3%) 156 (86.7%) 0.58 40 (88.9%) 217 (87.5%) 1.00 





























Atrial fibrillation 4 (3.7%) 6 (3.3%) 1.00 5 (4.4%) 5 (2.8%) 0.52 2 (4.4%) 8 (3.2%) 0.65 
Peripheral vascular disease 4 (3.7%) 12 (6.5%) 0.43 4 (3.5%) 12 (6.7%) 0.30 8 (17.8%) 8 (3.2%) 0.0008 
Medications, n (%) *  
Aspirin 101 (92.7%) 167 (90.7%) 0.67 107 (94.7%) 161 (89.4%) 0.14 41 (91.1%) 227 (91.5%) 1.00 
PY12 antagonist 19 (17.4%) 26 (14.1%) 0.50 21 (18.6%) 24 (13.3%) 0.25 5 (11.1%) 40 (16.1%) 0.50 
Statin 102 (93.6%) 160 (86.9%) 0.08 103 (91.2%) 159 (88.3%) 0.56 42 (93.3%) 220 (88.7%) 0.44 
Beta Blocker 72 (66.1%) 124 (67.4%) 0.90 77 (68.1%) 119 (66.1%) 0.80 32 (71.1%) 164 (66.1%) 0.61 
ACEI/ARB 76 (69.7%) 121 (65.7%) 0.61 81 (71.7%) 116 (64.4%) 0.20 38 (84.4%) 159 (64.1%) 0.009 
Insulin 1 (0.9%) 3 (1.6%) 1.00 1 (0.9%) 3 (1.7%) 1.00 0  4 (1.4%) 1.00 
Oral diabetic medications 17 (15.6%) 31 (16.8%) 0.87 19 (16.8%) 29 (1.6%) 0.87 8 (17.8%) 40 (16.1%) 0.83 
CCB 23 (21.1%) 40 (21.7%) 1.00 27 (23.9%) 36 (20.0%) 0.47 12 (26.7%) 51 (20.6%) 0.43 
Diuretics 7 (6.4%) 31 (16.8%) 0.028 7 (6.2%) 31 (17.2%) 0.007 7 (15.6%) 31 (12.5%) 0.63 
Biomarkers, median (IQR)  
Total Cholesterol (mmol/L) 4.0 (3.5-4.7) 4.1 (3.6-4.8) 0.41 4.0 (3.5-
4.8) 
4.1 (3.6-4.7) 0.63 4.2 (3.5-4.9) 3.8 (4.1-4.7) 0.53 
LDL (mmol/L) 1.9 (1.3-2.5) 1.9 (1.2-2.4) 0.75 1.7 (1.2-
2.5) 
2.1 (1.4-2.4) 0.21 2.2 (1.2-2.7) 1.9 (1.2-2.4) 0.12 
HDL (mmol/L) 1.2 (1.0-1.7) 1.2 (1.0-1.8) 0.76 1.2(1.0-1.7) 1.2 (1.0-1.7) 0.69 1.2 (1.0-1.7) 1.2 (1.0 –1.7) 0.74 
TAG (mmol/L) 1.5 (1.1-2.5) 1.6 (1.1-2.2) 0.87 1.5(1.0-2.5) 1.5 (1.1-2.2) 0.87 1.4 (1.2-2.0) 1.6 (1.1-2.4) 0.37 
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Creatinine (µmol/L) 80 (70-94) 77 (70-89) 0.42 78(70-88) 78(70-92) 0.95 80 (70-91) 77 (70-90) 0.48 
CAD, n (%)  
Non-obstructive disease (<50%) 
 
Single vessel disease 
 
Two vessel disease 
 




















































































Coronary Stent, n (%) 83 (76.1%) 135 (73.4%) 0.68 85 (75.2%) 133 (73.9%) 0.89 24 (53.3%) 194 (78.2%) 0.0013 
Segment involvement score. 
Median (IQR) 
6 (4-8) 5 (3-7) 0.008 4 (6-8) 5(3-7) 0.002 7 (6-9) 5 (3-7) <0.0001 





























































<0.0001 N/A N/A N/A 
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N/A N/A 1.4  
(1.23-1.62) 
1.2 (1.1-1.4) <0.0001 
TBR≥1.28 86 (78.9%) 27 (14.7%) 0.0001 N/A N/A N/A 26 (57.8%) 87 (35.1%) 0.005 
CCS>1199 27 (24.8%) 19 (10.3%) 0.0015 26 (23.0%) 20 (11.1%) 0.0082 N/A N/A N/A 
Risk scores  
REACH score (IQR) CV event 13 (11-15) 13 (11-15) 0.075 14 (12-16) 12 (10-15) 0.0039 15 (13-17) 13 (11-15) <0.0001 










0.0074 8.5 (6.3-11.0) 5.4 (4.7-8.5) <0.0001 
REACH score (IQR) CV death 11 (10-13) 11 (9-13) 0.015 11 (10-13) 11 (9-12) 0.0012 12 (11-14) 11 (9-12) <0.0001 










0.0011 2.3 (1.8-3.8) 1.8 (1.1 -2.3) <0.0001 
Duke score 4 (3-5) 4 (3-5) 0.28 4 (3-5) 4 (3-5) 0.0324 5 (4-5) 4 (3-5) 0.0024 
SMART risk score 21 (15-27) 17 (12-24) 0.0050 20 (14-28) 17 (13-24) 0.0414 24 (18-32) 17 (13-24) 0.0002 
Outcomes 
Myocardial infarction 16 (14.7%) 4 (2.2%) 0.0001 16 (14.2%) 4 (2.2%) 0.0002 13 (15.6%) 7 (5.2%) 0.08 
MACE 23 (21.1%) 17 (9.2%) 0.008 23 (20.4) 17 (9.4%) 0.0078 10 (22.2%) 30 (12.1%)  0.10 
Stroke 3 9 0.045 3 9 0.045 1 11 0.003 
Cardiovascular death 2 1 N/A 2 1 N/A 0 3 N/A 
Delayed revascularization 2 3 N/A 2 3 N/A 0 5 N/A 
28 
 
ACEI/ARB – angiotensin converting enzyme inhibitor/angiotensin receptor blocker, ACS – acute coronary syndrome, CABG – coronary 
artery bypass graft, CAD – coronary artery disease, CMA – coronary microcalcification activity, CVA - Cerebrovascular accident, MACE 
– major adverse cardiovascular event, PCI – percutaneous coronary intervention, REACH - Reduction of Atherothrombosis for Continued 
Health, SMART Secondary Manifestations of Arterial Disease, SIS – segment involvement score, TAG - triacylglycerides, TBR – target 
to background ratio, TIA - transient ischemic attack  












Target to background ratio 
>1.28 




p-value Hazard ratio (95% 
CI) 
p-value Hazard ratio 
(95% CI) 
p-value 
Model 1 7.30 (2.44-21.84) <0.001 6.16 (1.06-18.42) 0.001 3.24 (1.29-8.11) 0.012 
Model 2 7.20 (2.36-21.95) 0.001 5.94 (1.94-18.10) 0.002 -  
Model 3  6.66 (2.19-20.25) 0.001 5.57 (1.80-17.00) 0.003 2.65 (0.93-7.56) 0.069 
Model 4 8.73 (2.44-31.29) 0.001 4.80 (1.54-14.93) 0.007 2.72 (0.90-8.21) 0.075 
Model 5 8.91 (2.47-32.16) 0.001 4.83 (1.54-15.20) 0.007 -  
Model 6 8.12 (2.57-25.28) p<0.001 4.30 (1.34-13.82) 0.014   
Model 7 7.10 (2.2-25.1) 0.003 4.6 (1.4-14.4) 0.013   
Model 1 – unadjusted; Model 2 – adjusted for Coronary Calcium Score; Model 3 – adjusted for segment involvement score, number of 
coronary stents, multivessel coronary artery disease; Model 4 – adjusted for segment involvement score, number of coronary stents, 
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multivessel coronary artery disease, age, gender, hyperlipidaemia, hypertension, diabetes, smoking; Model 5 – similar to Model 4 and 
additionally adjusted for coronary calcium scoring; Model 6 – similar to Model 5 and additionally adjusted for REACH and SMART 
risk scores. Model 7 – similar to model 6 and additionally adjusted for initial patient’s presentation (stable vs acute myocardial infarction) 
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REACH and SMART risk scores 
REACH score. “REACH (REduction of Atherothrombosis for Continued Health) is an 
outpatient registry of patients with either stable symptomatic vascular disease (CAD, 
cerebrovascular disease, or peripheral artery disease) or with multiple atherosclerotic risk factors. 
The data collected from 3647 centers in 29 countries enabled establishing the REACH score 
which enables prediction of 20-month risk of a recurrent cardiovascular event (1). The REACH 
score calculator can be found at: https://www.u-prevent.com/en-
GB/ReachCalculator/ReachCalculator 
SMART Score.  The SMART (Second manifestations of arterial disease) risk score estimates 
the 10-year risk for myocardial infarction, stroke or vascular death in individual patients with 
previous cardiovascular disease, including coronary artery disease, cerebrovascular disease, 
peripheral artery disease, abdominal aortic aneurysm and polyvascular disease. The SMART risk 
score was developed in a population of vascular patients in the Netherlands that were included in 
the Secondary Manifestations of Arterial Disease (SMART)-study (2). External validation and 
updating were performed in pooled trial cohorts of 18,436 vascular patients from W-Europe, S-
Europe, Israel, USA, Canada, Mexico, S-Africa, Australia, and N-Zealand (3). The SMART 








Coronary motion correction compensates for coronary artery motion by aligning all gates to the 
end-diastolic position and has already demonstrated its ability to reduce image noise and 
improve the reproducibility of acquired data (4). In the first step of motion correction, anatomical 
coronary artery data was extracted from coronary CT angiography by applying a vessel tracking 
algorithm based on Bayesian maximal paths (Autoplaque version 2.0). Secondly, a 
diffeomorphic mass-preserving image registration algorithm was used to align the 4 gates of PET 
data to the end-diastolic gate (FusionQuant Software, Cedars-Sinai Medical Center, Los 
Angeles). After motion correction, the 4 gates were summed together to build a motion-free 
image containing counts from the entire PET acquisition. 
 
Blood clearance -correction 
To offset for the variation in injection to scan delay that has a major impact on blood pool 
activity, we used a recently validated correction factor to harmonize the background activity to a 
reference 60-minute injection to acquisition interval  
𝑆𝑆𝑆𝑆𝑆𝑆𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵  𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝑐𝑐𝐵𝐵𝑐𝑐𝑐𝑐𝐵𝐵 = 𝑆𝑆𝑆𝑆𝑆𝑆𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 ∗ 𝑒𝑒−0.004∗(60−𝑐𝑐) 







Prediction of fatal and non-fatal myocardial infarction in stable patients and subjects with 
recent myocardial infarction 
Over 42 [31-49] months of follow-up, 13 of 232 stable patients experienced a fatal or non-fatal 
myocardial infarction. Similar to the entire cohort patients, 18F-NaF uptake measured using the 
CMA approach had the biggest area under the receiver operator curve (Online Figure 3). On Cox 
proportional modelling only CMA and coronary calcium scores emerged as predictors of 
outcome: HR=23.2 95% CI (3.0-178.5), p=0.003 and HR=5.7 95% CI (1.9-16.8), p=0.002 
respectively. Importantly neither the Duke modified index [HR=2.0 95% CI (0.65-6.11), p=0.23] 
nor the REACH [HR=1.5 95% CI (0.2-11.5, p=0.70] or SMART [HR=2.8 95% CI (0.8-10.3), 
p=0.11] risk scores showed such predictive capabilities. With only 7 myocardial infarctions in 61 
patients imaged recently after myocardial infarction, none of the covariates emerged as 
predictors of myocardial infarction. However, in this population, CMA once again demonstrated 
the most favorable hazard ratios of the factors assessed (HR=3.1 (95% CI (0.7-15.9) p=0.18) 
compared to TBR HR=1.5 (95% CI (0.3-6.6) p=0.60), coronary calcium scores HR=0.9 (95% CI 
(0.2-43.2) p=0.68) and clinical variables (all p>0.50). When patients were divided according to 
the time from myocardial infarction to PET imaging, we observed no difference in CMA values 
between those scanned within 13 days from the adverse event and those who underwent PET at 






























































































Age <40 <50 <18 
DM N/A insulin-dependent 







Excluded Excluded Excluded 
ACS within the last 
12 months 
Excluded N/A N/A 
Dual anti-platelet 
therapy or warfarin or 
NOAC 
Excluded N/A N/A 
PCI/CABG within 
the last 3 months (or 
Excluded N/A N/A 
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plan for PCI/CABG 
in the next 12 
months) 
Bleeding diathesis Excluded N/A N/A 






Excluded Excluded Excluded 
Inability to provide 
informed consent 











EF<35% or Class III 
congestive heart 
failure 





Online Table 3. Baseline Characteristics of Study Participants. Comparison of patients with 
(coronary microcalcification activity [CMA] > 0) and without (CMA = 0) increased coronary 
18F-NaF uptake. 
 
 Entire Cohort CMA=0 (n=90) CMA>0 
(n=203) 
 
Age in years, mean (SD) 65 (9) 63 (9) 65 (9) P=0.0803 
Men, n (%) 245 (84%) 71 (78.9%) 174 (86.1%) p=0.1712 
Body-mass index (kg/m2), 
mean (SD) 
29 (5) 29 (5) 29 (5) P=1.0000 
Systolic blood pressure (mm 
Hg), mean (SD) 
141 (20) 137 (19) 144 (20) P=0.0054 
Diastolic blood pressure (mm 
Hg), mean (SD) 
79 (11) 78 (9) 80 (12) P=0.1584 
Cardiovascular history, n (%)  
History of ACS 161 (55.1 %) 56 (62.2%) 105 (51.7%) P=0.0749 
History of PCI 237 (80.9 %) 57 (63.3%) 126 (62.1%) P=0.8963 
History of CABG 48 (16.4 %) 16 (17.8%) 32 (15.8%) P=0.7326 
History of angina 136 (46.6 %) 48 (53.3%) 88 (43.43%) P=0.1283 
CVA/TIA 9 (3.1 %) 2 (2.2%) 7 (3.4%) P=0.7264 





Hypertension 174 (59.6 %) 47 (52.2%) 128(63.1%) P=0.0936 
Hyperlipidemia 257 (88 %) 81 (90.0 %) 177 (87.2%) P=0.1571 
Diabetes Mellitus 61 (20.8 %) 16 (17.8%) 35 (22.2%) P=1.0000 
Current smoking 
Ex-smoker 








Atrial fibrillation 10 (3.4 %) 5 (5.6 %) 5 (2.5%) P=0.1827 
Peripheral vascular disease 16 (5.5 %) 7 (7.8%) 9 (4.4%) P=0.2698 
Medications, n (%) *  
Aspirin 268 (91.8 %) 81 (90.0%) 187 (92.1%) P=0.8185 
P2Y12 antagonist 45 (15.4 %) 12 (13.3%) 33 (16.3%) P=0.6005 
Statin 262 (89.7 %) 80 (86.7%) 183 (90.1%) P=0.8348 
Beta Blocker 196 (67.1 %) 64 (71.1%) 133 (65.5%) P=0.4184 
ACEI/ARB 197 (67.4 %) 64 (71.1%) 134 (66.0%) P=0.4194 
Insulin 4 (1.4 %) 0 (0%) 4 (2.0%) P=0.3161 
Oral diabetic medications 48 (16.4 %) 17 (18.8%) 31 (15.2%) P=0.4943 
Calcium channel blockers 63 (21.6 %) 17 (18.9%) 46 (22.7%) P=0.5388 
Diuretics 38 (16.0 %) 12 (13.3%) 10 (4.9%) 0.0162 
Biomarkers, median (IQR)  
Total Cholesterol (mmol/L) 4.1 (3.6-4.7) 4.1 (3.7-4.8) 4.1 (3.5-4.7) P=0.81034 
LDL (mmol/L) 1.9 (1.2-2.4) 1.9 (1.3-2.3) 1.9 (1.2- 2.5) P=0.93624 
HDL (mmol/L) 1.2 (1-1.7) 1.1 (0.9-1.6) 1.3 (1.0-1.7) P=0.08186 
TAG (mmol/L) 1.5 (1.1-2.3) 1.6 (1.1-2.4) 1.5 (1.1-2.3) P=0.52218 
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Creatinine (µmol/L) 0.9 (0.8-1.0) 0.9 (0.8-1.0) 0.9 (0.8-1.0) P=0.80258 
CAD, n (%)  
Non-obstructive 
disease (<50%) 
- Single-vessel disease 
- Two-vessel disease 
- Three-vessel disease 
- LMS involvement 
15 (5.1 %) 
87 (29.8 %) 
110 (37.7 %) 
81 (27.6 %) 
















Coronary Stent, n (%) 218 (73.4%) 61 (67.8%) 157 (77.3%) P=0.1099 
Segment involvement score. 
Median (IQR) 
5 (3-7) 5 (3-7) 6 (4-7) P=0.0562 

























Modified Duke CAD index 
(IQR) 
4 (3-5) 4 (3-5) 4 (3-5) P=0.0574 
Coronary Calcium Score, 
median (IQR) 
334 (76-804) 179 (48-529) 378 (103-993) P=0.0027 






























TBR, median (IQR) 1.22 (1.1-
1.42) 
1.05 (0.99-1.11) 1.29 (1.19-1.48) P<0.0001 
TBR>1.28 113 (38.6%) 6 (6.7%) 107 (52.7%) P=0.0001 
CMA, median (IQR) 0.66 (0-2.84) 0 0.89 [0.47-3.10] P<0.0001 
Coronary Calcium 
Score>1000 
59 (20.1%) 9 (10.0%) 50 (24.6%) P=0.0042 
Coronary Calcium 
Score>1199 
46 (15.7%) 9 (10.0%) 37 (18.2%) P=0.0831 
REACH score CV event 
(IQR) 
13 (11-15) 12 (10-14) 13 (11-15) P=0.08012 
SMART risk score % (IQR) 18 (13-26) 17 (13-23) 19 (13-27) P=0.0285 
MI during follow-up 20 (6.8%) 0 (0%) 20 (9.9%) P=0.0007 
MACE during follow-up 40 (13.6%) 7 (7.8%) 33 (16.3%) P=0.0643 
ACEI/ARB – angiotensin converting enzyme inhibitor/angiotensin receptor blocker, ACS – 
acute coronary syndrome, CABG – coronary artery bypass graft, CAD – coronary artery disease, 
CMA – coronary microcalcification activity, CVA - Cerebrovascular accident, MACE – major 
adverse cardiovascular event, PCI – percutaneous coronary intervention, REACH - Reduction of 
Atherothrombosis for Continued Health, SMART Secondary Manifestations of Arterial Disease, 
SIS – segment involvement score, TAG - triacylglycerides, TBR – target to background ratio, 
TIA - transient ischemic attack  
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Online Table 4. Comparison of patient with and without myocardial infarction (MI) or coronary 
heart disease death during follow-up. 
 Fatal or non-fatal 
myocardial 
infarction (n=20) 




Age in years, mean (SD) 64 (9) 65 (9) P=0.6318 
Men, n (%) 18 (90%) 227 (83.5%) P=0.5465 
Body-mass index (kg/m2), mean (SD) 30 (5) 29 (5) P=0.3886 
Systolic blood pressure (mm Hg), mean 
(SD) 
144 (23) 141 (20) P=0.5222 
Diastolic blood pressure (mm Hg), 
mean (SD) 
78 (14) 79 (11) P=0.7007 
Cardiovascular history, n (%)    
H of ACS 9 (45%) 153 (55.4%) P=0.3603 
H of PCI 17 (85%) 220 (80.6%) P=0.4821 
H of CABG 5 (25%) 43 (15.6%) P=0.3424 
H of angina 13 (65%) 123 (44.6%) P=0.1049 
CVA/TIA 2 (10%) 7 (2.5%) P=0.1187 
Comorbidities/risk factors, n (%)    
HTN 17 (85%) 158 (57.9%) P=0.0179 
HPL 19 (95%) 239 (87.5%) P=0.4859 
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Atrial fibrillation 1 (5%) 9 (3.3%) P=0.5125 
Peripheral vascular disease 2 (10%) 14 (4.1%) P=0.2994 
Medications, n (%) *    
Aspirin 18 (90%) 251 (91.9%) P=0.6729 
P2Y12 antagonist 11 (55%) 34 (12.5%) P<0.0001 
Statin 19 (95%) 244 (89.4) P=0.7050 
Beta Blocker 14 (70%) 183 (67%) P=1.0000 
ACEI/ARB 13 (65%) 152 (55.7%) P=0.4889 
Insulin 0 (0%) 4 (1.5%) P=1.0000 
Oral diabetic medications 6 (30%) 42 (15.4%) P=0.1123 
CCB 7 (35%) 56 (20.5%) P=0.1571 
Diuretics 3 (15%) 33 (12.1%) P=0.7220 
Biomarkers, median (IQR)    
Total Cholesterol (mmol/L) 4 (3.0-4.6) 4.1 (3.6–4.8) P=0.4354 
LDL (mmol/L) 1.4 (0.9-
2.8) 
1.9 (1.3-2.4) P=0.1443 
HDL (mmol/L) 1.3 (1.0-
2.0) 
1.2 (1.0-1.7) P=0.54186 
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TAG (mmol/L) 2.0 (1.1-
2.3) 
1.5 (1.1 -2.3) P=0.4593 
Creatinine (µmol/L) 78 (69-88) 78 (70 – 91) P=0.85716 
CAD, n (%)    
- Non-obstructive disease (<50%) 
- Single vessel disease 
- Two vessel disease 
- Three vessel disease 





















Segment involvement score. Median 
(IQR) 
6 (4-8) 5 (3-7) P=0.25014 




















Duke index 5 (4-5) 4 (3-5) P=0.0536 
Coronary Calcium Score, 
median (IQR) 
  397 (39-1456) 331 (76-775) P=0.60306 
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TBR, median (IQR)    1.40 (1.28-1.77)        1.21 (1.09-1.40) P=0.0008 
CMA, median (IQR)    3.05 (1.62-5.25)          0.46 (0-2.47) P=0.00012 
TBR>1.275 16 (80%) 97 (36%) P=0.0002 
CMA>0 20 (100%) 183 (67%) P=0.0007 
CMA>1.56 16 (80%) 93 (34.1%) P=0.0001 
Coronary Calcium Score>1000 7 (35%) 52 (19.0%) P=0.0001 
REACH score CV event (IQR) 13 (11-15) 13 (11-15) P=0.79486 
SMART risk score 20 (13-28) 18 (13-26) P=0.5157 
ACEI/ARB – angiotensin converting enzyme inhibitor/angiotensin receptor blocker, ACS – 
acute coronary syndrome, CABG – coronary artery bypass graft, CAD – coronary artery disease, 
CMA – coronary microcalcification activity, CVA - Cerebrovascular accident, MACE – major 
adverse cardiovascular event, PCI – percutaneous coronary intervention, REACH - Reduction of 
Atherothrombosis for Continued Health, SMART Secondary Manifestations of Arterial Disease, 
SIS – segment involvement score, TAG - triacylglycerides, TBR – target to background ratio, 
TIA - transient ischemic attack  




Online Table 5. Comparison of patients scanned shortly after myocardial infarction (unstable) 
and those who had stable coronary artery disease at the time of imaging. 
 Stable (n=232) Unstable (n=61)  
Age in years, mean (SD) 66 (8) 62 (9) P=0.0008 
Men, n (%) 188 (81%) 57 (93.4%) P=0.0288 
Body-mass index (kg/m2), 
mean (SD)  
30 (5) 28 (5) P=0.0058 
Systolic blood pressure (mm 
Hg), mean (SD) 
145 (19) 130 (19) P<0.0001 
Diastolic blood pressure (mm 
Hg), mean (SD) 
80 (11) 76 (13) P=0.0157 
Cardiovascular history, n (%)    
H of ACS 153 (65.9 %) 9 (14.8%) P<0.0001 
H of PCI 176 (75.9 %) 7 (11.5%) P<0.0001 
H of CABG 46 (19.8 %) 2 (3.3%) P=0.0008 
H of angina 127 (54.7 %) 9 (14.8%) P<0.0001 
CVA/TIA 6 (2.6 %) 3 (4.8%) P=0.4004 
Comorbidities/risk factors, n 
(%) 
   
HTN 143 (61.6 %) 32 (52.5%) P=0.2404 
HPL 224 (96.6 %) 34 (55.7%) P<0.0001 





33 (14.2 %) 





Atrial fibrillation 6 (2.6 %) 4 (6.6%) P=0.2250 
Peripheral vascular disease 14 (6.0 %) 2 (3.3%) P=0.5375 
Medications, n (%)*    
Aspirin 221 (95.3 %) 48 (78.7%) P=0.0002 
PY12 antagonist 11 (4.7 %) 34 (55.7%) P<0.0001 
Statin 217 (93.5 %) 46 (75.4%) P=0.0002 
Beta Blocker 160 (69.0 %) 37 (60.7%) P=0.2238 
ACEI/ARB 169 (72.9 %) 29 (47.5%) P=0.0003 
Insulin  3 (1.3 %) 1 (1.6%) P=1.0000 
Oral diabetic medications 43 (18.5 %) 5 (8.2%) P=0.0537 
CCB  56 (24.1 %) 7 (11.5%) P=0.0354 
Diuretics 29 (12.5 %) 9 (14.8%) P<0.0001 
Biomarkers, median (IQR)    
Total Cholesterol (mmol/L) 4.0 (3.6-4.7) 4.4 (3.5-5.0) P<0.04884 
LDL (mmol/L) 2.1 (1.5-2.5) 1.5 (0.8) P<0.0001 
HDL (mmol/L) 1.2 (1.0-1.5) 2.2 (1.2) P<0.0001 
TAG (mmol/L) 1.5 (1.1-2.2) 2.2 (1.5) P=0.02088 
Creatinine (µmol/L) 77 (70-89) 86 (24) P=0.31732 





- Single vessel disease 
- Two vessel disease 
- Three vessel disease 




60 (25.9 %) 
95 (40.9 %) 
63 (27.2 %) 













Coronary Stent, n (%) 
Anywhere 
 






Segment involvement score. 
Median (IQR) 
6 (4-7) 4 (2-7) P=.00438 




















CCS, median (IQR) 416 (104-937) 106 (7-355) P<0.00001 




















TBR, median (IQR) 1.21 (1.1- 1.4) 1.23 (1.15-1.45) P= 0.15272  
CMA, median (IQR) 0.40 (0-2.75) 1.23 (0.22-3.00) P=0.03  
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CMA>0 151 (65%) 52 (85%) P=0.0028 
CMA>1.56 82 (35.3%) 27 (52.6%) P=0.2340 
TBR>1.275 84 (36,1%) 29 (47.5%) P=0.1389 
CCCS>1000 54 (23.3%) 5 (8.2%) P=0.0045 
CCCS>1199 42 (18.1%) 3 (4.9%) P=0.0091 
REACH score (IQR) CV event 13 (11-15) 12 (11-15) P=0.06724 
20-month risk of next CV 
event, % (IQR) 
6.3 (4.7-8.5) 5.4 (4.4-7.9) P=0.08364 
REACH score (IQR) CV death 11 (10-13) 11 (9-13) P=0.09492 
20-month cardiovascular 
death, % (IQR) 
1.8 (1.4-3.0) 1.8 (1.1-2.7) P=0.11184 
Duke score 4 (3-5) 4 (3-5) P=0.2202 
SMART risk score (%) 20 (14-27)  13 (10-20) P=0.00014 
Infarct during follow-up 13 (6%) 7 (11%) P=0.18 
ACEI/ARB – angiotensin converting enzyme inhibitor/angiotensin receptor blocker, ACS – 
acute coronary syndrome, CABG – coronary artery bypass graft, CAD – coronary artery disease, 
CMA – coronary microcalcification activity, CVA - Cerebrovascular accident, MACE – major 
adverse cardiovascular event, PCI – percutaneous coronary intervention, REACH - Reduction of 
Atherothrombosis for Continued Health, SMART Secondary Manifestations of Arterial Disease, 
SIS – segment involvement score, TAG - triacylglycerides, TBR – target to background ratio, 
TIA - transient ischemic attack  




Online Table 6. Comparison of patients with and without major adverse cardiovascular events 
during follow-up. 





Age in years, mean (SD) 64 (9) 65 (9) P=0.5143 
Men, n (%) 36 (90%) 209 (82.9%) P=0.3567 
Body-mass index (kg/m2), 
mean (SD)  
29 (5) 29 (5) P=1.0000 
Systolic blood pressure (mm 
Hg), mean (SD) 
138 (21) 142 (20) P=0.2440 
Diastolic blood pressure 
(mm Hg), mean (SD) 
76 (13) 79 (11) P=0.1194 
Cardiovascular history, n (%)    
H of ACS 16 (40.0%) 146 (57.7%) P=0.0409 
H of PCI 36 (90.0%) 201 (79.4%) P=0.2836 
H of CABG 6 (15.0%) 42 (16.6%) P=1.0000 
H of angina 24 (60.0%) 112 (44.3%) P=0.1246 
CVA/TIA 4 (10.0%) 5 (2.0%) P=0.0227 
Comorbidities/risk factors, n 
(%) 
   
HTN 27 (67.5%) 148 (58.5%) P=0.3033 
HPL 34 (85.0 %) 224 (88.5%) P=0.5981 
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DM 11 (27.5 %) 50 (19.8%) P=0.2947 
Current smoking 
Ex-smoker 
7 (17.5 %) 





Atrial fibrillation 2 (5.0 %) 8 (3.2%) P=0.6315 
Peripheral vascular disease 6 (15.0%) 10 (4.0%) P=0.0126 
Medications, n (%) *    
Aspirin 36 (90.0%) 233 (92.1%) P=0.7547 
P2Y12 antagonist 18 (45.0%) 27 (10.7%) P<0.0001 
Statin 37 (92.5%) 226 (89.3%) P=0.7792 
Beta Blocker 26 (65.0%) 171 (67.6%) P=0.7213 
ACEI/ARB 23 (57.5%) 175 (69.1%) P=0.0924 
Insulin  1 (2.5%) 3 (1.2%) P=0.4459 
Oral diabetic medications 8 (20.0%) 40 (15.9%) P=0.4944 
CCB  13 (32.5%) 50 (19.8%) P=0.0953 
Diuretics 8 (20.0%) 30 (11.9%) 0=0.2012 
Biomarkers, median (IQR)    
Total Cholesterol (mmol/L) 4.0 (3.4-4.6) 4.1 (3.6-4.8) P=0.39532 
LDL (mmol/L) 1.6 (0.9-2.3) 2.0 (1.4-2.5) P=0.0455 
HDL (mmol/L) 1.6 (1.0-2.0) 1.2 (1.0-1.7) P=0.06432 
TAG (mmol/L) 1.5 (1.1-2.3) 1.5 (1.1-2.3) P=0.85716 
Creatinine (µmol/L) 78 (69-94) 78 (70-90) P=0.57548 





- Single-vessel disease 
- Two-vessel disease 
- Three-vessel disease 




















Coronary Stent, n (%) 29 (72.5%) 189 (74.7%) P=0.8455 
Segment involvement score. 
Median (IQR) 
5 (4-8) 6 (3-7) P=0.5485 











19 (7.5%)           
47 (18.6%)             
59 (23.3%)                







Duke index 4 (4-5) 4 (3-5) P=0.16452 




344 (81-801) P=0.4965 





















>1000 10 (25.0%) 49 (19.4%) P=0.3999 
TBR, median (IQR) 1.34 (1.13-
1.54) 
1.22 (1.10-1.40) P=0.07346 
CMA, median (IQR) 1.9 (1.65-
4.76) 
0.51 (0-2.42) P=0.00988 
TBR>1.28 23 (57.5%) 90 (35.6%) P=0.0135 
CMA>0 20 (50%) 170 (67%) P=0.0488 
CMA>1.56 23 (57.5%) 86 (34%) P=0.0076 
Coronary Calcium 
Score>1000 
10 (25%) 49 (19.4%) P=0.4012 
REACH score CV event 
(IQR)  
13 (11-15) 13 (11-15) P=0.6672 
SMART risk score % 19 (12-28) 18 (13-26) P=0.76418 
ACEI/ARB – angiotensin converting enzyme inhibitor/angiotensin receptor blocker, ACS – 
acute coronary syndrome, CABG – coronary artery bypass graft, CAD – coronary artery disease, 
CMA – coronary microcalcification activity, CVA - Cerebrovascular accident, MACE – major 
adverse cardiovascular event, PCI – percutaneous coronary intervention, REACH - Reduction of 
Atherothrombosis for Continued Health, SMART - Secondary Manifestations of Arterial 
Disease, SIS – segment involvement score, TAG - triacylglycerides, TBR – target to background 





Online Table 7. Uni- and multivariable Cox proportional regression models for prediction of 






Target to background 
ratio >1.275 











Model 1 2.29 (1.22-4.29) 0.01 2.08 (1.11-3.89) 0.02 1.94 (0.94-3.96) 0.071 
Model 2 2.36 (1.23-4.52) 0.01 2.09 (1.09-4.01) 0.027 -  
Model 3  2.19 (1.15-4.17) 0.017 2.06 (1.08-3.96) 0.029 1.93 (0.85-4.38) 0.115 
Model 4 2.08 (1.06-4.07) 0.033 1.79 (0.91-3.55) 0.093 1.68 (0.73-3.84) 0.221 
Model 5 2.46 (1.25-4.83) 0.009 2.06 (1.04-4.07) 0.038 -  
Model 6 2.10 (1.07-4.13) 0.030 1.80 (0.90-3.61) 0.098   
Model 1 – unadjusted; Model 2 – adjusted for Coronary Calcium Score; Model 3 – adjusted for 
segment involvement score, number of coronary stents, multivessel coronary artery disease; 
Model 4 – adjusted for segment involvement score, number of coronary stents, multivessel 
coronary artery disease, age, gender, hyperlipidemia, hypertension, diabetes, smoking; Model 5 – 
similar to Model 4 and additionally adjusted for coronary calcium scoring. Model 6 - similar to 




Online Table 8. Prediction of myocardial infarction and major adverse cardiovascular events 
(MACE) during follow-up. Area under the receiver-operator curve. 
 Myocardial Infarction MACE 
Area under receiver 
operator curve (95% CI) 
p-value Area under receiver 
operator curve (95% CI) 
p-value 
CMA 0.76 (0.67-0.84) <0.001 0.61 (0.52-0.71) 0.02 
TBR 0.72 (0.62-0.83) 0.001 0.59 (0.49-0.69) 0.07 
Coronary 
Calcium Score 
0.55 (0.38-0.69) 0.45 0.48 (0.38-0.59) 0.73 
REACH 0.52 (0.38-0.66) 0.77 0.48 (0.38-0.58) 0.70 
SMART 0.54 (0.41-0.68) 0.47 0.52 (0.42-0.62) 0.70 
Duke index 0.62 (0.49-0.74) 0.08 0.58 (0.48-0.67) 0.12 
Age 0.48 (0.35-0.60) 0.71 0.51 (0.38-0.64) 0.52 
CMA – coronary microcalcification activity, TBR – target to background ratio, REACH - 







Online Table 9. Prediction of myocardial infarction and major adverse cardiovascular events 
(MACE) during follow-up. Univariable Cox proportional regression models with covariates as 
continuous variables. 
 Myocardial Infarction MACE 
Hazard ratio (95% 
CI) 
p-value Hazard ratio (95% 
CI) 
p-value 
CMA 1.07 (1.03-1.12) 0.001 1.06 (1.01-1.10) 0.012 
TBR 2.57 (1.66-3.98) <0.001 2.08 (1.35-3.22) 0.001 
Coronary 
Calcium Score 
1.00 (1.00-1.01) 0.25 1.00 (1.00-1.00) 0.77 
REACH 1.00 (0.86-1.16) 0.99 0.96 (0.86-1.07) 0.96 
SMART 1.02 (0.98-1.06) 0.26 1.02 (0.99-1.05) 0.13 
Duke index 1.59 (0.99-2.48) 0.07 1.23 (0.94-1.62) 0.14 
Age 0.99 (0.94-1.04) 0.61 0.99 (0.95-1.03) 0.55 
CMA – coronary microcalcification activity, TBR – target to background ratio, REACH - , CI- 
Confidence interval, Reduction of Atherothrombosis for Continued Health, SMART - Secondary 






Online Table 10. Prediction of myocardial infarction and major adverse cardiovascular events 
(MACE) during follow-up by age and risk scores. 
CAD – Coronary Artery Disease, MACE – Major Adverse Cardiovascular Event, REACH - 






Age > 53.5 REACH risk score > 
17.5 
SMART risk score > 
18.5 
Duke CAD index > 4.5 
Hazard ratio 
(95% CI) 
p-value Hazard ratio 
(95% CI) 
p-value Hazard ratio 
(95% CI) 


























Online Figure 1. Measuring Disease Activity Across the Coronary Vasculature with 18F-
NaF Coronary Microcalcification Activity (CMA). 3-Dimensional rendering of coronary CT 
angiography with superimposed tubular whole vessel volumes of interest (light green) employed 
for evaluation of 18F-sodium fluoride uptake (blue and red). Compared to target to background 
ratio (TBR) measurements (which depend on single pixel tracer uptake), the coronary 
microcalcification activity (CMA) is a summary measure of 18F-NaF activity across the entire 
coronary vasculature as it includes all counts originating from the coronary arteries (uptake 











Online Figure 3. Receiver Operator Curve Analysis for the prediction of myocardial 
infarction in the study population (A), in patients with established stable coronary artery 
disease (B) and imaged shortly after myocardial infarction (C).  Receiver operator curves for 
myocardial infarction prediction by coronary 18F-NaF PET (CMA), CT coronary calcium score, 






Online Figure 4. Coronary disease activity and plaque burden in patients with and without 
future major adverse cardiovascular events. Coronary microcalcification activity (CMA, top 
row), maximum target to background ratios (TBR, middle row) and the coronary calcium scores 
(CCS, bottom row) in patients with and without MACE during follow-up. For the Kaplan-Meier 
curves patients were dichotomized according to thresholds derived from receiver operator curves 







Online Figure 5. Kaplan Meier Curve Analysis for the prediction of myocardial infarction 
in patients imaged shortly after myocardial infarction (A) and in patients with established 
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